Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Holding CRNX?
Track your performance easily
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$29.72 - $62.53
Previous Close$55.17
Volume493.58K
Average Volume (3M)701.37K
Market Cap
$5.12B
Enterprise Value$4.31B
Total Cash (Recent Filing)$862.67M
Total Debt (Recent Filing)$52.54M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 18, 2025EPS Estimate
-$0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding92,737,627
10 Day Avg. Volume810,670
30 Day Avg. Volume701,365
Standard Deviation0.16
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.14
Price to Sales (P/S)4884.12
Price to Cash Flow (P/CF)-19.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.14K
Enterprise Value/Gross Profit1.07K
Enterprise Value/Ebitda-15.33
Forecast
1Y Price Target
$77.13Price Target Upside37.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Crinetics Pharmaceuticals News
PremiumCompany Announcements
Crinetics Pharmaceuticals Announces Q3 2024 Financial Results
Ownership Overview
7.36% Insiders
26.59% Mutual Funds
36.76% Other Institutional Investors
15.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $29.72 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 117 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.911 by -$0.049.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.9.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 92,737,625 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.911. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 312M.
---
Crinetics Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.13 (37.56% Upside)
$77.13 (37.56% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.96%
12-Months-Change
Fundamentals
Return on Equity
-40.26%
Trailing 12-Months
Asset Growth
46.11%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q3 2024
0:00 / 0:00
---
CRNX Stock 12 Month Forecast
Average Price Target
$77.13
▲(37.56% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Ultragenyx Pharmaceutical
―
Fate Therapeutics
―
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+93.02%
reiterated a buy rating 9 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +93.02% per trade.
---